217 related articles for article (PubMed ID: 21434854)
1. Harnessing impaired energy metabolism in cancer cell: small molecule- mediated ways to regulate tumorigenesis.
Govardhan KS; Ramyasri K; Kethora D; Ravishekar Y; Prasenjit M
Anticancer Agents Med Chem; 2011 Mar; 11(3):272-9. PubMed ID: 21434854
[TBL] [Abstract][Full Text] [Related]
2. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.
Leu WJ; Swain ShP; Chan SH; Hsu JL; Liu SP; Chan ML; Yu CC; Hsu LC; Chou YL; Chang WL; Hou DR; Guh JH
Oncotarget; 2016 Nov; 7(47):76995-77009. PubMed ID: 27769069
[TBL] [Abstract][Full Text] [Related]
3. MYC and metabolism on the path to cancer.
Hsieh AL; Walton ZE; Altman BJ; Stine ZE; Dang CV
Semin Cell Dev Biol; 2015 Jul; 43():11-21. PubMed ID: 26277543
[TBL] [Abstract][Full Text] [Related]
4. Antagonistic role of natural compounds in mTOR-mediated metabolic reprogramming.
Cerella C; Gaigneaux A; Dicato M; Diederich M
Cancer Lett; 2015 Jan; 356(2 Pt A):251-62. PubMed ID: 24530513
[TBL] [Abstract][Full Text] [Related]
5. Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.
Liu Y; Wan WZ; Li Y; Zhou GL; Liu XG
Oncotarget; 2017 Jan; 8(4):7181-7200. PubMed ID: 27769061
[TBL] [Abstract][Full Text] [Related]
6. The miR-17∼92 microRNA Cluster Is a Global Regulator of Tumor Metabolism.
Izreig S; Samborska B; Johnson RM; Sergushichev A; Ma EH; Lussier C; Loginicheva E; Donayo AO; Poffenberger MC; Sagan SM; Vincent EE; Artyomov MN; Duchaine TF; Jones RG
Cell Rep; 2016 Aug; 16(7):1915-28. PubMed ID: 27498867
[TBL] [Abstract][Full Text] [Related]
7. The sweet trap in tumors: aerobic glycolysis and potential targets for therapy.
Yu L; Chen X; Wang L; Chen S
Oncotarget; 2016 Jun; 7(25):38908-38926. PubMed ID: 26918353
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.
Maira SM; Furet P; Stauffer F
Future Med Chem; 2009 Apr; 1(1):137-55. PubMed ID: 21426073
[TBL] [Abstract][Full Text] [Related]
9. Fubp1 supports the lactate-Akt-mTOR axis through the upregulation of Hk1 and Hk2.
Kang M; Lee SM; Kim W; Lee KH; Kim DY
Biochem Biophys Res Commun; 2019 Apr; 512(1):93-99. PubMed ID: 30871777
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial AKAP1 supports mTOR pathway and tumor growth.
Rinaldi L; Sepe M; Delle Donne R; Conte K; Arcella A; Borzacchiello D; Amente S; De Vita F; Porpora M; Garbi C; Oliva MA; Procaccini C; Faicchia D; Matarese G; Zito Marino F; Rocco G; Pignatiello S; Franco R; Insabato L; Majello B; Feliciello A
Cell Death Dis; 2017 Jun; 8(6):e2842. PubMed ID: 28569781
[TBL] [Abstract][Full Text] [Related]
11. The mitochondrial voltage-dependent anion channel 1 in tumor cells.
Shoshan-Barmatz V; Ben-Hail D; Admoni L; Krelin Y; Tripathi SS
Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2547-75. PubMed ID: 25448878
[TBL] [Abstract][Full Text] [Related]
12. Jolkinolide B inhibits glycolysis by downregulating hexokinase 2 expression through inactivating the Akt/mTOR pathway in non-small cell lung cancer cells.
Gao X; Han H
J Cell Biochem; 2018 Jun; 119(6):4967-4974. PubMed ID: 29384225
[TBL] [Abstract][Full Text] [Related]
13. Halofuginone inhibits colorectal cancer growth through suppression of Akt/mTORC1 signaling and glucose metabolism.
Chen GQ; Tang CF; Shi XK; Lin CY; Fatima S; Pan XH; Yang DJ; Zhang G; Lu AP; Lin SH; Bian ZX
Oncotarget; 2015 Sep; 6(27):24148-62. PubMed ID: 26160839
[TBL] [Abstract][Full Text] [Related]
14. Flavonoids Luteolin and Quercetin Inhibit RPS19 and contributes to metastasis of cancer cells through c-Myc reduction.
Chen KC; Hsu WH; Ho JY; Lin CW; Chu CY; Kandaswami CC; Lee MT; Cheng CH
J Food Drug Anal; 2018 Jul; 26(3):1180-1191. PubMed ID: 29976410
[TBL] [Abstract][Full Text] [Related]
15. Energy deregulation: licensing tumors to grow.
Garber K
Science; 2006 May; 312(5777):1158-9. PubMed ID: 16728625
[No Abstract] [Full Text] [Related]
16. Metabolic reprogramming and AMPKα1 pathway activation by caulerpin in colorectal cancer cells.
Yu H; Zhang H; Dong M; Wu Z; Shen Z; Xie Y; Kong Z; Dai X; Xu B
Int J Oncol; 2017 Jan; 50(1):161-172. PubMed ID: 27922662
[TBL] [Abstract][Full Text] [Related]
17. p53 and glucose metabolism: an orchestra to be directed in cancer therapy.
Gomes AS; Ramos H; Soares J; Saraiva L
Pharmacol Res; 2018 May; 131():75-86. PubMed ID: 29580896
[TBL] [Abstract][Full Text] [Related]
18. Emerging metabolic targets in cancer therapy.
Zhao Y; Liu H; Riker AI; Fodstad O; Ledoux SP; Wilson GL; Tan M
Front Biosci (Landmark Ed); 2011 Jan; 16(5):1844-60. PubMed ID: 21196269
[TBL] [Abstract][Full Text] [Related]
19. Oxidative phosphorylation as a target to arrest malignant neoplasias.
Rodríguez-Enríquez S; Gallardo-Pérez JC; Marín-Hernández A; Aguilar-Ponce JL; Mandujano-Tinoco EA; Meneses A; Moreno-Sánchez R
Curr Med Chem; 2011; 18(21):3156-67. PubMed ID: 21671858
[TBL] [Abstract][Full Text] [Related]
20. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
